| KATSE # | Lebitso la Sehlahiswa | Tlhaloso |
| CPD100587 | Philorizin | Phlorizin, eo hape e bitsoang phloridzin, ke glucoside ea phloretin, dihydrochalcone, lelapa la bicyclic flavonoids, eo hape e leng sehlotšoana sa mefuta e fapaneng ea phenylpropanoid synthesis ea limela. Phlorizin ke inhibitor ea tlhōlisano ea SGLT1 le SGLT2 hobane e hlōlisana le D-glucose bakeng sa ho tlama ho mojari; Sena se fokotsa ho tsamaisoa ha tsoekere ea renal, ho theola bongata ba tsoekere maling. Phlorizin e ile ea ithutoa e le pheko e ka bang teng ea meriana bakeng sa lefu la tsoekere la mofuta oa 2, empa haesale e nkeloa sebaka ke li-analogue tsa maiketsetso tse ikhethileng, tse kang canagliflozin le dapagliflozin. |
| CPD0045 | Ipragliflozin | Ipragliflozin, eo hape e tsejoang e le ASP1941, ke inhibitor e matla le e khethang ea SGLT2 bakeng sa kalafo ea lefu la tsoekere la mofuta oa 2. Phekolo ea Ipragliflozin e ntlafalitse taolo ea glycemic ha e eketsoa kalafong ea metformin mme e ka amahanngoa le ho theola boima ba 'mele le phokotso ea khatello ea mali ha e bapisoa le placebo. Ipragliflozin ha e ntlafatse hyperglycemia feela empa hape le lefu la tsoekere / botenya bo amanang le metabolic litoeba tsa mofuta oa 2 oa lefu la tsoekere. E ile ea amoheloa hore e sebelisoe Japane ka 2014 |
| CPD100585 | Tofogliflozin | Tofogliflozin, eo hape e tsejoang e le CSG 452, ke inhibitor e matla le e khethang haholo ea SGLT2 e ntseng e tsoela pele kalafong ea lefu la tsoekere. Tofogliflozin e ntlafatsa taolo ea glycemic le ho theola boima ba 'mele ho bakuli ba nang le lefu la tsoekere la mofuta oa 2. Tofogliflozin e hatella ho kenella ha tsoekere ka har'a lisele tsa tubula e itšetlehileng ka tekanyetso. Ho pepeseha ha tsoekere e phahameng (30?mM) bakeng sa 4 le 24?h ho ile ha eketsa haholo tlhahiso ea khatello ea oxidative liseleng tsa tubular, tse neng li hatelloa ke kalafo ea tofogliflozin kapa antioxidant N-acetylcysteine (NAC). |
| CPD100583 | Empagliflozin | Empagliflozin, e tsejoang hape e le BI10773 (lebitso la khoebo la Jardiance), ke moriana o amohetsoeng bakeng sa ho alafa lefu la tsoekere la mofuta oa 2 ho batho ba baholo ka 2014. E entsoe ke Boehringer Ingelheim le Eli Lilly and Company. Empagliflozin ke inhibitor ea sodium glucose co-transporter-2 (SGLT-2), mme e etsa hore tsoekere e maling e monoe ke liphio ebe e ntšoa ka moroto. Empagliflozin ke inhibitor ea sodium glucose co-transporter-2 (SGLT-2), e fumanehang feela ka har'a li-proximal tubules tsa likarolo tsa nephronic liphio. SGLT-2 e etsa karolo ea 90 lekholong ea ho kenngoa ha tsoekere maling. |
| CPD100582 | Canagliflozin | Canagliflozin (INN, lebitso la khoebo Invokana) ke setlhare sa kalafo ea lefu la tsoekere la mofuta oa 2. E entsoe ke Mitsubishi Tanabe Pharma 'me e rekisoa tlas'a laesense ke Janssen, karolo ea Johnson & Johnson. Canagliflozin ke inhibitor ea subtype 2 sodium-glucose transport protein (SGLT2), e ikarabellang bonyane 90% ea ho kenngoa ha tsoekere ka liphio. Ho thibela sepalangoang sena ho etsa hore tsoekere ea mali e tsoe ka moroto. Ka Hlakubele 2013, canagliflozin e bile inhibitor ea pele ea SGLT2 ho amoheloa United States. |
| CPD0003 | Dapagliflozin | Dapagliflozin, eo hape e tsejoang e le BMS-512148, ke setlhare se sebelisoang ho alafa lefu la tsoekere la mofuta oa 2 se amohetsoeng ka 2012 ke FDA. Dapagliflozin e thibela mofuta oa 2 oa liprotheine tse tsamaisang tsoekere ea sodium (SGLT2) tse ikarabellang bonyane 90% ea ho kenngoa ha tsoekere ka liphio. Ho thibela mochine ona oa lipalangoang ho etsa hore tsoekere ea mali e tlosoe ka moroto. Litekong tsa bongaka, dapagliflozin e theotse HbA1c ka 0.6 ha e bapisoa le karolo ea placebo ha e kenngoa ho metformin. |
